MicroRNAs as potential liquid biopsy biomarkers in colorectal cancer: A systematic review.
MicroRNAs as potential liquid biopsy biomarkers in colorectal cancer: A systematic review.
复制标题
DOI：
10.1016/j.bbcan.2018.05.006
复制
发表时间：
2018-12
期刊：
影响因子：
--
通讯作者：
Goel A
中科院分区：
文献类型：
--
作者：
Toiyama Y;Okugawa Y;Fleshman J;Richard Boland C;Goel A
新出现的证据已经证明了循环miRNA作为诊断结直肠癌的稳健的非侵入性生物标志物的可行性。使用循环miRNA进行结直肠癌（CRC）的早期检测特别令人感兴趣，因为它可以为筛查结肠镜检查提供潜在的补充方法。然而，循环miRNA作为“液体活检”生物标志物用于发展成临床筛选测试的发展受到几个问题的阻碍。本文综述了miRNA生物标志物在结直肠癌（CRC）液体活检中的临床应用现状，并讨论了其在结直肠腺瘤（CRA）和CRC患者筛查中的应用。在此，我们对PubMed和科克伦数据库中2002年1月1日至2017年12月31日的引文进行了系统检索，作为本研究的电子来源。对所有已发表的研究进行筛选，不限制语言、日期或国家。我们使用了以下索引术语和文本词的数据库特定组合，包括：microRNA、结直肠癌、血清、血浆和外泌体。基于这些检索，我们总结了CRC中miRNA诊断生物标志物的当前知识状态的进展和显著特征，并重点关注试图优化理想方法以进一步推进其作为液体活检用于临床的文章。我们的结论是，非编码RNA领域，特别是作为液体活检检测的miRNA的临床应用正在迅速成熟，并且这些基因组特征很有希望在不久的将来发展成为临床可行的检测，用于结直肠癌患者的早期检测和临床管理。
Emerging evidence has demonstrated the feasibility of circulating miRNAs as robust non-invasive biomarkers for the diagnosis in colorectal cancer. The use of circulating miRNAs for the early detection of colorectal cancer (CRC) is of particular interest as it can offer a potential complementary approach to screening colonoscopy. However, the development of circulating miRNAs as “liquid biopsy” biomarkers for development into clinical screening tests has been hampered by several issues. In this article, we summarize the status of this field for the clinical utilization of miRNA biomarkers as liquid biopsies in colorectal cancer (CRC) and discuss their applications as screening tests for patients with colorectal adenoma (CRA) and CRC. Herein, we undertook a systematic search for citations in PubMed and the Cochrane Database from January 1, 2002 through December 31, 2017 as electronic sources for this study. All published studies were screened with no restriction on language, date, or country. We used database-specific combinations of the following index terms and text words, including: microRNA, colorectal cancer, serum, plasma, and exosomes. Based upon these searches, we summarize the progress and salient features of the current state of knowledge of miRNA diagnostic biomarkers in CRC, and focuses on the articles that attempt to optimize ideal methodologies to further advance their as liquid biopsies for clinical use. We conclude that the field of noncoding RNAs, particularly for the clinical use of miRNAs as liquid biopsy assays is maturing rapidly, and it is highly promising that these genomic signatures will likely be developed into clinically-viable tests for the early detection and clinical management of patients with colorectal cancer in the not so distant future.
登录
查看更多内容
影响因子：
4.3
作者：
Corbisier, Philippe;Pinheiro, Leonardo;Mazoua, Stephane;Kortekaas, Anne-Marie;Chung, Pui Yan Jenny;Gerganova, Tsvetelina;Roebben, Gert;Emons, Hendrik;Emslie, Kerry
通讯作者：
Emslie, Kerry
影响因子：
9
作者：
Carter JV;Roberts HL;Pan J;Rice JD;Burton JF;Galbraith NJ;Eichenberger MR;Jorden J;Deveaux P;Farmer R;Williford A;Kanaan Z;Rai SN;Galandiuk S
通讯作者：
Galandiuk S
影响因子：
39.2
作者：
Ahlquist DA;Sargent DJ;Loprinzi CL;Levin TR;Rex DK;Ahnen DJ;Knigge K;Lance MP;Burgart LJ;Hamilton SR;Allison JE;Lawson MJ;Devens ME;Harrington JJ;Hillman SL
通讯作者：
Hillman SL
影响因子：
--
作者：
Chang PY;Chen CC;Chang YS;Tsai WS;You JF;Lin GP;Chen TW;Chen JS;Chan EC
通讯作者：
Chan EC
影响因子：
9
作者：
Kanaan, Ziad;Roberts, Henry;Galandiuk, Susan
通讯作者：
Galandiuk, Susan